General Information of the Compound
Compound ID
CP0182748
Compound Name
6-[5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazol-3-yl]pyridine-3-carbonitrile
    Show/Hide
Synonyms
453566-30-8
6-(5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazol-3-yl)nicotinonitrile
AZD 6538
AZD-6538
AZD6538
BDBM50395922
CHEMBL2164552
GTPL6440
SCHEMBL4186520
    Show/Hide
Structure
Formula
C15H6FN5O
Molecular Weight
291.245
Canonical SMILES
Fc1cc(cc(c1)-c1nc(no1)-c1ccc(cn1)C#N)C#N
    Show/Hide
InChI
InChI=1S/C15H6FN5O/c16-12-4-10(7-18)3-11(5-12)15-20-14(21-22-15)13-2-1-9(6-17)8-19-13/h1-5,8H
    Show/Hide
InChIKey
PBVKGEMPZBKZOA-UHFFFAOYSA-N
Physicochemical Property
logP
2.68106
Rotatable Bonds
2
Heavy Atom Count
22
Polar Areas
99.39
Hydrogen Bond Donor Count
0
Hydrogen Bond Acceptor Count
6
Complexity
22

"RO5" indicates the cutoff set by lipinski's rule of five:

(1) Molecular weight less than 500 Dalton;

(2) xlogp less than 5;

(3) No more than 5 hbonddonor (Hydrogen Bond Donor Count);

(4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count);

(5) No more than 10 rotbonds (Rotatable Bond Count).

    Show/Hide
Click to Show/Hide the External Link(s) of This Compound
PubChem ID
CID: 9879103
SID: 14845123
ChEMBL ID
CHEMBL2164552
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound

Compound
Cell Line
Protein

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT01247, Metabotropic glutamate receptor 5
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000006 HEK293 Homo sapiens (Human)  1
1
IC50 = 3.2 nM
   TI
   LI
   LO
   TS
Biochemical Assays
1 IC50 = 14.5 nM
Protein ID: PT00854, Metabotropic glutamate receptor 5
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000006 HEK293 Homo sapiens (Human)  4
1
IC50 = 13.4 nM
   TI
   LI
   LO
   TS
2
IC50 = 51 nM
   TI
   LI
   LO
   TS
3
Ki = 17.9 nM
   TI
   LI
   LO
   TS
4
Ki = 28 nM
   TI
   LI
   LO
   TS
Clinical Information about the Compound
Drug 1 ( AZD-6538 )
Drug Name AZD-6538
Company AstraZeneca plc
Indication
Gastroesophageal reflux disease
Discontinued in Phase 1